Abstract 1059P
Background
The impact of the duration of tumor persistence within the host – tumor longevity (TL) – on patient (pt) outcomes under immune checkpoint inhibitors (ICIs) is unexplored. We hypothesized that this time parameter may influence ICIs efficacy. We investigated this association in head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), and renal/urothelial cancer (R/UC) pts.
Methods
Retrospective, observational study including adult pts with primary/recurrent HNSCC, NSCLC, R/UC receiving ICIs (≥first line) in 2 Italian centers. Endpoints were the association between TL and: 1) progressive disease (PD) vs. complete response (CR)/ partial response (PR)/ stable disease (SD); 2) Common Terminology Criteria for Adverse Events (CTCAE) G≥3 toxicity; 3) overall survival (OS). Univariable/multivariable logistic regression model (for PD, toxicity) and Cox proportional hazards model (for OS) were used. TL, defined as time from cancer histological diagnosis to ICIs start, was included as continuous variable using 3 knots restricted cubic spline, comparing third (Q3) vs. first (Q1) quartiles.
Results
304 pts, diagnosed in 2002-2022, started ICIs in 2014-2022. TL had a right-skewed distribution [median: 15.3 (Q1-Q3, 5.5; 33.1) months]. CR, PR, SD, PD occurred in 16 (5.3%), 90 (29.6%), 65 (21.4%), 133 (43.7%) pts, respectively; G≥3 toxicity was reported in 16 (5.3%) pts and 231 (76.0%) pts died. Multivariable models adjusted for relevant variables (Table) suggested that longer TL was associated with lower PD odds (Odds Ratio [OR] Q3 vs. Q1 = 0.31; 95% CI 0.12; 0.81, p = 0.004), higher G≥3 toxicity odds (OR = 1.27; 95% CI 0.39; 4.12), lower death risk (Hazard Ratio = 0.79; 95% CI 0.49; 1.28). Table: 1059P
| Descriptive statistics (N=304) | ||
| Sex | Male | 243 (79.9%) |
| Age at diagnosis (years) | Mean (SD) | 64.7 (10.4) |
| Smoking history | Yes | 226 (74.3%) |
| No | 57 (18.8%) | |
| Unknown | 21 (6.9%) | |
| Primary site | NSCLC | 138 (45.4%) |
| HNSCC | 112 (36.5%) | |
| R/UC | 54 (17.8%) | |
| Stage at diagnosis | IV | 199 (65.5%) |
ConclusionsOur real-world, hypothesis-raising results indicate that longer TL may lead to improved response to ICIs, higher risk of G≥3 toxicity and longer OS. Clinical trial identificationEditorial acknowledgementLegal entity responsible for the studyThe authors. FundingAuthors at Niguarda Cancer Center are supported by Fondazione Oncologia Niguarda ETS. DisclosureA. Sartore Bianchi: Financial Interests, Personal, Advisory Board: Amgen, Servier, Novartis; Financial Interests, Personal, Invited Speaker: Bayer, Guardant Health, Pierre Fabre. S. Siena: Financial Interests, Advisory Board: Agenus, Amgen, AstraZeneca, Bayer, BMS, CheckmAb, Clovis, Daiichi Sankyo, Merck, Novartis, Roche-Genentech, Seattle Genetics. L.F.L. Licitra: Financial Interests, Personal, Advisory Board, for expert opinion in advisory boards: AstraZeneca, Bayer, BMS, Eisai, MSD, Boehringer Ingelheim, F. Hoffmann-La Roche Ltd, Novartis, Roche, Debiopharm International SA, Sobi, Incyte Biosciences Italy srl, Doxa Pharma srl, Amgen, Nanobiotics, GSK; Financial Interests, Institutional, Research Grant, Funds received by my institution for clinical studies and research activities in which I am involved: AstraZeneca, BMS, Boehringer Ingelheim, Celgene International, Eisai, Exelixis, Debiopharm International SA, F. Hoffmann-La Roche ltd, IRX Therapeutics, Medpace, Merck-Serono, Merck Healthcare KGaA, MSD, Novartis, Pfizer, Roche, Adlai Nortye. All other authors have declared no conflicts of interest. Resources from the same session1024P - Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumorsPresenter: Stephane Champiat Session: Poster session 03 1025P - Fully intravenous delivery regimen of oncolytic adenovirus coding for TNFa and IL-2 (TILT-123) in patients with advanced solid cancersPresenter: Santeri Pakola Session: Poster session 03 1026P - Updated results from the phase I 1456-0001 study for intratumoral (IT) VSV-GP (BI 1831169) in patients with advanced solid tumorsPresenter: Stephane Champiat Session: Poster session 03 1027P - First results for intravenous (IV) VSV-GP (BI 1831169) in patients (pts) with advanced solid tumors from the 1456-0001 studyPresenter: Marc Oliva Bernal Session: Poster session 03 1028P - A phase I study of personalized KSX01-TCRT therapy for advanced solid tumor and its mechanismsPresenter: Shuhang Wang Session: Poster session 03 Resources: Abstract 1029P - Preclinical development of TCR-modified T cell therapies against mutated KRASPresenter: Hugh Salter Session: Poster session 03 1030P - Survival rates in high-risk neuroblastoma patients undergoing anti-GD2 immunotherapy: A single arm meta-analysis and systemic reviewPresenter: Lorena Escalante Romero Session: Poster session 03 1032P - Tumor-infiltrating lymphocytes with inducible membrane-tethered IL-12 cultured in optimized media exhibits superior anti-tumor activityPresenter: Patrick Innamarato Session: Poster session 03 1033P - Anti-tumor efficacy and safety of conditionally activated armored CAR-T cells against gastrointestinal tumorsPresenter: Zhihong Huang Session: Poster session 03 1034P - Preclinical development of genetically modified tumor-infiltrating lymphocytes using biopsy samples from liver cancer patientsPresenter: Mingyu Liu Session: Poster session 03 This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
|